All true and...
Well first we have to show efficacy. We are confounded by crossover(like Frovenge) but crossover may also help us say with visual proof that the vaccine elicits an immune response. The new radio-graphic imaging can see this as well as other diagnostic tools. To show a before and after of DCVAX. The transition to other solid tumors may not be that big of a leap. Direct PH2 is chomping at the bit. PH 1 showed multiple different tumor types and why wouldn't, it is tailor made. You ever buy a 1 size fits all suit? It has already been proven safe and the entire body of work for DCVAX could help NWBO in my opinion with some accelerated pathway for all tumor locations. It may not work in "All Solid Tumors" rather in "All Solid Tumors" with certain genetic characteristics none of which having anything to do with where it is located on the body. Combo's could broaden the genetic characteristics that DCVAX works with. We have to stop calling it breast, skin, lung and start calling it by what really makes them similar.
News 
Market Data 
Discover 
